CG Oncology (NASDAQ:CGON – Get Free Report) had its price objective boosted by Wedbush from $84.00 to $91.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush‘s target price suggests a potential upside of 7.34% from the company’s current price.
Several other analysts have also issued reports on CGON. Piper Sandler increased their target price on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Royal Bank Of Canada downgraded CG Oncology from an “outperform” rating to a “sector perform” rating and boosted their price target for the company from $80.00 to $97.00 in a research note on Tuesday. Truist Financial upped their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Guggenheim reduced their price objective on shares of CG Oncology from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. Finally, Wall Street Zen raised shares of CG Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, CG Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $92.56.
Check Out Our Latest Research Report on CGON
CG Oncology Price Performance
CG Oncology (NASDAQ:CGON – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.55 million. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. On average, sell-side analysts anticipate that CG Oncology will post -3.00 EPS for the current fiscal year.
Insider Activity at CG Oncology
In related news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total transaction of $62,060.00. Following the completion of the sale, the director directly owned 1,000 shares in the company, valued at $62,060. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.80% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Aquatic Capital Management LLC raised its stake in CG Oncology by 111.2% during the third quarter. Aquatic Capital Management LLC now owns 24,435 shares of the company’s stock worth $1,732,000 after acquiring an additional 12,867 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of CG Oncology by 32.5% in the third quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock worth $80,564,000 after acquiring an additional 278,751 shares during the last quarter. Toronto Dominion Bank lifted its holdings in shares of CG Oncology by 177.7% in the third quarter. Toronto Dominion Bank now owns 798,676 shares of the company’s stock worth $56,618,000 after acquiring an additional 511,044 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of CG Oncology in the 3rd quarter valued at approximately $4,665,000. Finally, Marshall Wace LLP boosted its stake in shares of CG Oncology by 179.8% in the 3rd quarter. Marshall Wace LLP now owns 11,708 shares of the company’s stock valued at $830,000 after purchasing an additional 7,523 shares in the last quarter. Institutional investors own 26.56% of the company’s stock.
CG Oncology News Roundup
Here’s some of the latest news about CGON:
- Positive Sentiment: In the PIVOT-006 trial, cretostimogene reduced the risk of bladder-cancer recurrence by 68% versus surveillance, meeting the primary endpoint with a hazard ratio of 0.32 (p<0.0001). The study enrolled 367 patients with intermediate-risk and high-grade Ta disease, a population of about 50,000 for which the company says there are no FDA-approved adjuvant treatments. Reuters article
- Positive Sentiment: The treatment’s reported safety profile was favorable: no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results strengthen the case for cretostimogene as a potential treatment across a broader range of bladder-cancer patients. CG Oncology announcement
- Positive Sentiment: CG Oncology expects to use PIVOT-006 data in a second biologics license application (BLA), targeted for Q2 2027. The company also plans to broaden its initial BLA for BCG-unresponsive disease to include high-grade papillary-only patients, with submission completion expected by March 2027.
About CG Oncology
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-GuĂ©rin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Further Reading
- Five stocks we like better than CG Oncology
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
